...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current drug targets. CNS and neurological disorders >The Endocannabinoid System and Huntington's Disease.
【24h】

The Endocannabinoid System and Huntington's Disease.

机译：内源性大麻素系统和亨廷顿舞蹈病。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The research in Huntington's disease (HD) has been growing exponentially during the last decade, since the discovery of the genetic basis that leads to neurodegeneration. HD is one of several progressive neurodegenerative disorders, in which the underlying mutation is a CAG expansion encoding a polyglutamine tract in a specific protein, which in the case of HD, is called huntingtin. The first clinical symptoms of HD are generally psychiatric abnormalities, most commonly depression and mood disturbances. Involuntary choreiform movements and dementia develop over the next 15-20 years, and death generally results from complications derived from immobility. There is currently no cure, or even an effective therapy to offset the decline in mental and motor capabilities suffered by those affected by HD, but recent studies have started to examine the usefulness of different classes of new compounds. Among these, plant-derived, synthetic or endogenous cannabinoids have been proposed to have therapeutic value for the treatment of HD, since they act on cannabinoid CB(1) receptors located in the basal ganglia circuitry, that is affected by the striatal atrophy typical of HD. Recent studies have characterized the changes in these receptors, as well as their endogenous ligands, in the basal ganglia in a variety of animal models of HD. The results are indicative that the endocannabinoid system becomes hypofunctional in this disease, which could be related to the hyperkinesia typical of the earliest phases of this disease. In addition, it has been proposed that the loss of these receptors might be involved in the process of pathogenesis itself. This, together with the well-known protective properties of cannabinoid-related compounds, suggest that, in addition to a symptomatic usefulness, cannabinoids might also serve to delay or to arrest the development of this disease. The present article will review all recent data dealing with the biochemical, pharmacological and therapeutic bases that support a potential role of cannabinoids in the pathogenesis and/or therapeutic treatment of this motor disorder.
机译：自从发现导致神经退行性变的遗传基础以来，过去十年来亨廷顿舞蹈病（HD）的研究呈指数增长。 HD是几种进行性神经退行性疾病之一，其中潜在的突变是在特定蛋白质中编码聚谷氨酰胺束的CAG扩展，在HD的情况下称为亨廷顿蛋白。 HD的最初临床症状通常是精神异常，最常见的是抑郁和情绪障碍。在接下来的15-20年中，非自愿性舞蹈样运动和痴呆症会发展，并且死亡通常是由于不动引起的并发症。目前尚无治愈方法，甚至没有有效的疗法来抵消受HD影响的人精神和运动能力的下降，但是最近的研究已经开始研究不同类别的新化合物的有效性。其中，植物来源的，合成的或内源性的大麻素已被建议具有治疗HD的价值，因为它们对位于基底神经节回路中的大麻素CB（1）受体起作用，受典型的纹状体萎缩的影响高清最近的研究已在各种HD动物模型中表征了基底神经节中这些受体及其内源性配体的变化。结果表明，内源性大麻素系统在该疾病中功能减退，这可能与该疾病最早阶段的典型运动亢进有关。另外，已经提出这些受体的丢失可能与发病机理本身有关。这与大麻素相关化合物的众所周知的保护特性一起表明，除有症状的用途外，大麻素还可用于延缓或阻止这种疾病的发展。本文将回顾所有有关支持大麻素在该运动障碍的发病机理和/或治疗中的潜在作用的生化，药理和治疗基础的最新数据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号